PKM and ovarian carcinoma: Another study explored how reducing PKM2 levels affects ovarian cancer cells sensitivity to PARPi that have shown therapeutic success in advanced ovarian carcinomavia inhibiting homologous recombination (HR) pathway (Gomez et al., 2020).